Psilocybin for Addiction: Alcohol, Smoking, and the Research Evidence
About This Video
Psilocybin's applications for addiction may ultimately prove more impactful than its depression research. This Johns Hopkins video covers the two most advanced addiction lines: alcohol use disorder and tobacco (smoking) cessation. The smoking cessation data are particularly striking — a 2014 Johns Hopkins pilot study showed 80% abstinence at 6 months, compared to roughly 35% for varenicline (Chantix), the most effective approved smoking cessation medication.
The mechanism proposed for addiction is distinct from the depression mechanism, though related. Addiction involves rigid, compulsive behavioral patterns that resist cognitive override — what researchers call 'psychological inflexibility.' Psilocybin appears to interrupt this rigidity by temporarily dissolving the default mode network's self-narrative, creating a window in which people can observe their relationship to the addictive substance with unusual clarity. Many participants report a shift in identification — from 'I am a smoker' to 'I used to smoke' — that happens during the session and persists.
Key Takeaways
- Johns Hopkins smoking cessation trial showed 80% abstinence at 6 months — substantially higher than any approved smoking cessation medication.
- Alcohol use disorder trials show significant reductions in drinking days and heavy drinking days compared to both placebo and standard treatment.
- The proposed mechanism involves disrupting psychological inflexibility — the rigid self-narrative that maintains addictive identity.
- Most participants report the experience of 'deciding' to change, rather than being pharmacologically compelled — the insight appears to be the therapeutic mechanism.
- Opioid use disorder research is earlier-stage but underway; ibogaine (not psilocybin) has the stronger opioid addiction evidence base.
Dive Deeper
Continue exploring this topic on LearnShrooms: